Taigen Biopharmaceuticals Holdings Limited announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was TWD 29.618 million compared to TWD 553.208 million a year ago. Operating loss was TWD 258.397 million compared to operating Income of TWD 260.425 million a year ago. Net loss was TWD 343.210 million compared to net income of TWD 746.378 million a year ago. Basic loss per share was TWD 0.48 compared to basic earnings per share of TWD 1.04 a year ago. Diluted eps was TWD 0 compared to TWD 1.04 a year ago.